Loading...

AB-Biotics

BME:ABB
Snowflake Description

Exceptional growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ABB
BME
€69M
Market Cap
  1. Home
  2. ES
  3. Pharmaceuticals & Biotech
Company description

AB-Biotics, S.A. operates in the biotechnology industry in Spain. The last earnings update was 89 days ago. More info.


Add to Portfolio Compare Print
  • AB-Biotics has significant price volatility in the past 3 months.
ABB Share Price and Events
7 Day Returns
11%
BME:ABB
1.7%
ES Biotechs
-1.5%
ES Market
1 Year Returns
59.5%
BME:ABB
-9.2%
ES Biotechs
-5.9%
ES Market
ABB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
AB-Biotics (ABB) 11% 28.5% 26.1% 59.5% 246.9% 113.5%
ES Biotechs 1.7% 0.7% 1.3% -9.2% 28.5% 47.3%
ES Market -1.5% -1.2% -2.9% -5.9% 8.9% -19.3%
1 Year Return vs Industry and Market
  • ABB outperformed the Biotechs industry which returned -9.2% over the past year.
  • ABB outperformed the Market in Spain which returned -5.9% over the past year.
Price Volatility
ABB
Industry
5yr Volatility vs Market

ABB Value

 Is AB-Biotics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for AB-Biotics. This is due to cash flow or dividend data being unavailable. The share price is €5.55.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for AB-Biotics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are AB-Biotics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BME:ABB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €0.10
BME:ABB Share Price ** BME (2019-06-18) in EUR €5.55
Europe Biotechs Industry PE Ratio Median Figure of 29 Publicly-Listed Biotechs Companies 20.68x
Spain Market PE Ratio Median Figure of 138 Publicly-Listed Companies 17.17x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of AB-Biotics.

BME:ABB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BME:ABB Share Price ÷ EPS (both in EUR)

= 5.55 ÷ 0.10

56.75x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AB-Biotics is overvalued based on earnings compared to the Europe Biotechs industry average.
  • AB-Biotics is overvalued based on earnings compared to the Spain market.
Price based on expected Growth
Does AB-Biotics's expected growth come at a high price?
Raw Data
BME:ABB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 56.75x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 23 Publicly-Listed Biotechs Companies 1.2x
Spain Market PEG Ratio Median Figure of 79 Publicly-Listed Companies 1.59x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for AB-Biotics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on AB-Biotics's assets?
Raw Data
BME:ABB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €0.55
BME:ABB Share Price * BME (2019-06-18) in EUR €5.55
Spain Biotechs Industry PB Ratio Median Figure of 6 Publicly-Listed Biotechs Companies 3.38x
Spain Market PB Ratio Median Figure of 185 Publicly-Listed Companies 1.64x
BME:ABB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BME:ABB Share Price ÷ Book Value per Share (both in EUR)

= 5.55 ÷ 0.55

10.08x

* Primary Listing of AB-Biotics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AB-Biotics is overvalued based on assets compared to the ES Biotechs industry average.
X
Value checks
We assess AB-Biotics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. AB-Biotics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ABB Future Performance

 How is AB-Biotics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
61.9%
Expected annual growth in earnings per share.
Earnings growth vs Low Risk Savings
Is AB-Biotics expected to grow at an attractive rate?
  • AB-Biotics's earnings growth is expected to exceed the low risk savings rate of 1.5%.
Growth vs Market Checks
  • AB-Biotics's earnings growth is expected to exceed the Spain market average.
  • AB-Biotics's revenue growth is expected to exceed the Spain market average.
Annual Growth Rates Comparison
Raw Data
BME:ABB Future Growth Rates Data Sources
Data Point Source Value (per year)
BME:ABB Future Earnings per Share Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 61.9%
BME:ABB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 21.6%
Europe Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 19.8%
Spain Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 6.4%
Spain Market Earnings Growth Rate Market Cap Weighted Average 7.8%
Spain Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BME:ABB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BME:ABB Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 19 1
2019-12-31 14 1
BME:ABB Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 13 1 1
2018-09-30 11 2 0
2018-06-30 9 3 -1
2018-03-31 8 2 -1
2017-12-31 8 0 -1
2017-09-30 7 -1 -2
2017-06-30 6 -2 -2
2017-03-31 6 -2 -4
2016-12-31 5 -2 -6
2016-09-30 5 -1 -5
2016-06-30 5 0 -5
2016-03-31 5 0 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • AB-Biotics's earnings are expected to grow significantly at over 20% yearly.
  • AB-Biotics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BME:ABB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from AB-Biotics Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BME:ABB Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 0.34 0.34 0.34 1.00
2019-12-31 0.15 0.15 0.15 1.00
BME:ABB Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 0.10
2018-09-30 0.03
2018-06-30 -0.04
2018-03-31 -0.06
2017-12-31 -0.07
2017-09-30 -0.13
2017-06-30 -0.18
2017-03-31 -0.34
2016-12-31 -0.50
2016-09-30 -0.45
2016-06-30 -0.55
2016-03-31 -0.34

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • AB-Biotics is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess AB-Biotics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Spain market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
AB-Biotics has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ABB Past Performance

  How has AB-Biotics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare AB-Biotics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • AB-Biotics's year on year earnings growth rate has been positive over the past 5 years.
  • AB-Biotics has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • AB-Biotics has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
AB-Biotics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from AB-Biotics Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BME:ABB Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 12.59 1.22 1.84
2018-09-30 10.73 0.36 1.65
2018-06-30 8.86 -0.50 1.47
2018-03-31 8.29 -0.70 1.57
2017-12-31 7.72 -0.89 1.67
2017-09-30 6.87 -1.53 1.86
2017-06-30 6.02 -2.17 2.05
2017-03-31 5.56 -4.08 2.04
2016-12-31 5.10 -5.99 2.03
2016-09-30 5.27 -5.46 1.92
2016-06-30 5.44 -4.93 1.80
2016-03-31 5.00 -3.08 1.82
2015-12-31 4.55 -1.24 1.84
2015-09-30 3.86 -1.09 0.97
2015-06-30 3.17 -0.94 0.96
2015-03-31 2.77 -1.24 1.35
2014-12-31 2.38 -1.53 1.74
2014-09-30 2.10 -1.52 2.18
2014-06-30 1.81 -1.50 1.76
2014-03-31 1.54 -1.65 1.61
2013-12-31 1.27 -1.81 1.47
2013-06-30 1.09 -2.09 1.86
2013-03-31 1.91 -2.08 1.84
2012-12-31 2.72 -2.07 1.83
2012-06-30 5.48 -1.66 3.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • AB-Biotics has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • AB-Biotics used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • AB-Biotics has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess AB-Biotics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
AB-Biotics has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ABB Health

 How is AB-Biotics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up AB-Biotics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • AB-Biotics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • AB-Biotics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of AB-Biotics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 21.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from AB-Biotics Company Filings, last reported 5 months ago.

BME:ABB Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 6.86 0.33 2.77
2018-09-30 6.86 0.33 2.77
2018-06-30 5.43 0.45 3.99
2018-03-31 5.43 0.45 3.99
2017-12-31 4.74 0.59 2.45
2017-09-30 4.74 0.59 2.45
2017-06-30 4.76 0.88 0.85
2017-03-31 4.76 0.88 0.85
2016-12-31 5.57 1.02 2.73
2016-09-30 5.57 1.02 2.73
2016-06-30 2.48 1.21 0.19
2016-03-31 2.48 1.21 0.19
2015-12-31 7.12 1.20 0.65
2015-09-30 7.12 1.20 0.65
2015-06-30 7.35 1.28 0.93
2015-03-31 7.35 1.28 0.93
2014-12-31 8.68 1.48 1.78
2014-09-30 8.68 1.48 1.78
2014-06-30 9.10 0.00 2.61
2014-03-31 9.10 0.00 2.61
2013-12-31 9.95 1.83 3.11
2013-06-30 8.55 4.52 3.23
2013-03-31 8.55 4.52 3.23
2012-12-31 10.87 2.13 4.75
2012-06-30 7.00 3.37 0.49
  • AB-Biotics's level of debt (4.9%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (18.2% vs 4.9% today).
  • Debt is well covered by operating cash flow (287.9%, greater than 20% of total debt).
  • Interest payments on debt are not well covered by earnings (EBIT is 1.3x annual interest expense, ideally 3x coverage).
X
Financial health checks
We assess AB-Biotics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. AB-Biotics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ABB Dividends

 What is AB-Biotics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from AB-Biotics dividends. Estimated to be 0% next year.
If you bought €2,000 of AB-Biotics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate AB-Biotics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate AB-Biotics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BME:ABB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
Spain Market Average Dividend Yield Market Cap Weighted Average of 77 Stocks 4.4%
Spain Minimum Threshold Dividend Yield 10th Percentile 1.2%
Spain Bottom 25% Dividend Yield 25th Percentile 2.2%
Spain Top 25% Dividend Yield 75th Percentile 5.2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BME:ABB Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as AB-Biotics has not reported any payouts.
  • Unable to verify if AB-Biotics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of AB-Biotics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as AB-Biotics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of AB-Biotics's dividends in 3 years as they are not expected to pay a notable one for Spain.
X
Income/ dividend checks
We assess AB-Biotics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can AB-Biotics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. AB-Biotics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ABB Management

 What is the CEO of AB-Biotics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sergi Audivert Brugué
CEO Bio

Mr. Sergi Audivert Brugué serves as a Co-Founder, Co-Chief Executive Officer and Director at AB-Biotics SA and served as its Chief Operating Officer. Mr. Audivert serves as Chairman of AB-Biotics S.A. Mr. Audivert serves as a Secretary General and Director of Ability Pharmaceuticals, S.L.

CEO Compensation
  • Insufficient data for Sergi to compare compensation growth.
  • Insufficient data for Sergi to establish whether their remuneration is reasonable compared to companies of similar size in Spain.
Management Team

Sergi Audivert Brugué

TITLE
Co-Founder

Miquel Àngel Sierra

TITLE
Co-Founder

Moises Gonzalez

TITLE
Chief Financial Officer

Mercè Mengual

TITLE
Marketing Director

Carlos de Lecea

TITLE
Managing Director

Jordi Riera

TITLE
Chief Business Development Officer

José de Paz

TITLE
Non-Board Secretary
Board of Directors

Miquel Àngel Sierra

TITLE
Co-Founder

Juan Ramos Raich

TITLE
Independent Director

Sergi Audivert Brugué

TITLE
Co-Founder

José Echarri Torres

TITLE
Independent Director

Philip Claes

TITLE
Director

Hitoshi Yahara

TITLE
Director

Kazuhiko Fujii

TITLE
Director

Shinji Mizusawa

TITLE
Director

Agustí Mas

TITLE
Independent Director

Buenaventura Lopez

TITLE
Consultant
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess AB-Biotics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. AB-Biotics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ABB News

Simply Wall St News

Who Are The Major Shareholders In AB-Biotics SA (BME:ABB)?

I am going to take a deep dive into AB-Biotics SA’s (BME:ABB) most recent ownership structure, not a frequent subject of discussion among individual investors. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment. … BME:ABB Ownership Summary August 10th 18

Simply Wall St -

Why You Need To Look At This Factor Before Buying AB-Biotics SA. (BME:ABB)

If you are looking to invest in AB-Biotics SA.’s (BME:ABB), or currently own the stock, then you need to understand its beta in order to understand how it can affect the risk of your portfolio. … ABB's beta implies it may be a stock that investors with high-beta portfolios might find relevant if they wanted to reduce their exposure to market risk, especially during times of downturns. … How ABB's assets could affect its beta An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive.

Simply Wall St -

Who Are The Top Investors In AB-Biotics SA. (BME:ABB)?

In this article, I'm going to take a look at AB-Biotics SA.’s (BME:ABB) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … Insider Ownership Insiders form another group of important ownership types as they manage the company's operations and decide the best use of capital. … Thus, investors not need worry too much about the consequences of these holdings.Next Steps: ABB's considerably high level of institutional ownership calls for further analysis into its margin of safety.

Simply Wall St -

Did AB-Biotics SA.'s (BME:ABB) Recent Earnings Growth Beat The Trend?

After reading AB-Biotics SA.'s (BME:ABB) most recent earnings announcement (30 June 2017), I found it useful to look back at how the company has performed in the past and compare this against the latest numbers. … View our latest analysis for AB-Biotics How ABB fared against its long-term earnings performance and its industry I prefer to use data from the most recent 12 months, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … Each year, for the past five years AB-Biotics's top-line has risen by a mere 9.18%, on average.

Simply Wall St -

ABB Company Info

Description

AB-Biotics, S.A. operates in the biotechnology industry in Spain. The company offers probiotic products, including cardio metabolic products comprising AB-LIFE, AB LIFE Forte, AB-LIFE Plus, and LipiGO; oral care products that include AB-Dentalac, AB-Dentalac Pro, AB-Dentalac Junior, and AB-Dentisanium; pediatric products, such as AB-Kolicare and AB-Digest Kids; i3.1 gastrointestinal product; gynecology and urological products consisting of AB-Intimus and AB-Cyscare; and dermatology and immunology products, which include AB-Immuno and AB-Sakei 65. It also provides genetic tests for behavioral health, pain medicine, and fertility, as well as lab services. AB-Biotics, S.A. was founded in 2004 and is based in Barcelona, Spain.

Details
Name: AB-Biotics, S.A.
ABB
Exchange: BME
Founded: 2004
€69,132,331
12,456,276
Website: http://www.ab-biotics.com
Address: AB-Biotics, S.A.
Esade Creapolis,
Av. de la Torre Blanca, 57 – Desp. 3B06,
Barcelona,
Catalonia, 08172,
Spain
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BME ABB Series A shares Bolsas y Mercados Espanoles ES EUR 20. Jul 2010
Number of employees
Current staff
Staff numbers
33
AB-Biotics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/18 21:24
End of day share price update: 2019/06/18 00:00
Last estimates confirmation: 2019/03/21
Last earnings filing: 2019/03/21
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.